Preventing the devil's downfall

Genome of the Tasmanian devil contagious cancer sheds light on disease origin and spread

Preventing the devil's downfall

Researchers have sequenced the genome of a contagious cancer that is threatening the Tasmanian devil, the world's largest carnivorous marsupial, with extinction. Cataloguing the mutations present in the cancer has led to clues about where the cancer came from and how it became contagious.

The research has revealed that the cancer, which is spread between animals by biting, first arose from the cells of a single female Tasmanian devil. This animal is nicknamed 'The Immortal Devil' because although she died more than 15 years ago, her DNA is living on in the contagious cancer cell line that she spawned. The cancer causes the appearance of tumours on the face of affected devils which grow rapidly and cause death within months.

"The Tasmanian devil cancer is the only cancer that is threatening an entire species with extinction. Sequencing the genome of this cancer has allowed us to catalogue the mutations that caused this cancer to arise and to persist in the Tasmanian devil population."

Dr Elizabeth Murchison, lead author from the Wellcome Trust Sanger Institute

taz.jpgdoi: 10.1016/j.cell.2011.11.065
Map of genetic variation found in the spread of the Tasmanian devil cancer

The team found evidence for genetic differences between tumours, indicating that the cancer has genetically diverged during its spread through the Tasmanian devil population. They searched for these genetic differences between the tumours of 69 different devils from distant locations in Tasmania, allowing them to build up a map of the cancer's spread through the devil population. This indicates that some cancer sub-types may be more virulent than others.

"We found that devil cancer's genome has about 20,000 mutations. This is fewer mutations than are found in some human cancers and indicates that cancers do not need to be extremely unstable in order to become contagious. Tracing the evolutionary history and spread of this cancer helps us to understand not only what caused this disease but also to predict how it might behave in the future."

Dr David Bentley, senior co-author from Illumina Cambridge Ltd

The spread of cancer between individuals is normally prevented by the immune system, which can normally detect foreign tissues as 'non-self'. The team found some intriguing clues as to how the devil cancer may outwit the immune system, including mutations in a set of genes involved in immunity. However, future studies will be required to elucidate how cancer escapes the immune destruction.

"This research is important because it allows us to understand the pattern of disease spread and this may help contain the epidemic. However, we also now need to use the genome sequence to understand more about how this cancer became transmissible. Cancers that transmit through populations are obviously incredibly rare, but we should use the Tasmanian devil example to understand the process to be prepared in the extremely unlikely event that such an epidemic ever occurs in humans."

Professor Mike Stratton, senior author and Director of the Wellcome Trust Sanger Institute

The next stage of the research will be to map the genomes of thousands of devil tumours in order to understand the genetic diversity present in the cancer and to investigate the genetic interactions between the cancer and the Tasmanian devil population.

Notes to Editors
  • Genome sequencing and analysis of the Tasmanian devil and its transmissible cancer.

    Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ et al.

    Cell 2012;148;4;780-91


This work was supported in part by a Wellcome Trust, Dr Eric Guiler Tasmanian Devil Research and a L'Oreal UNESCO For Women in Science Fellowship, UK and Ireland (EPM).

Participating Centres

A list of participating centres can be found on the paper.

Selected Websites
Contact the Press Office

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Emily Mobley, Media Officer

Tel +44 (0)1223 496 851

Wellcome Sanger Institute,
CB10 1SA,

Mobile +44 (0) 7900 607793

Recent News

Sanger’s cloud computing wins award

High performance computing community recognises pioneering work of Sanger’s scientific IT teams

Wellcome Genome Campus wins silver watermark to recognise its support for public engagement

Award reflects work to nurture a culture where public engagement is supported and encouraged

Largest study of CRISPR-Cas9 mutations creates prediction tool for gene editing

Prediction resource could make CRISPR-Cas9 editing more reliable